O-114 Safety and efficacy of using combined interferons alpha 2b and gamma for treatment of basal cell carcinoma at a Clinical Surgical Hospital Salvador Allende Havana, Cuba
Author(s):
N McKenzie , M Edwards
Year of Presentation:
2026
Objective: To evaluate the efficacy and safety of using
combined interferon alpha 2b and gamma (HeberFERON)
in patients with basal cell carcinomas.
Methods: A phase IV, open-label, non-randomized, singlegroup clinical trial on 20 patients with a clinical and histological diagnosis of basal cell carcinoma. 10.5 mIU of HeberFeron was administered perilesionally 3 times weekly for 3 weeks. Outcome measures evaluated were clinical and histological resolution of tumour along with the duration of tumour resolution.
Results: 70% of patients were males, and 85% of patients were Phototype III. Age ranged from 46 to 94 years, with mean age of 78.5 years. 90% of patients presented with a single lesion, 50% affecting the nose followed by almost 30% affecting the ear. 75% of patients had a clinical and histological diagnosis of a nodular subtype while 25% were ulcerative. After complete treatment of 27 doses of HeberFeron, there was complete clinical and histological resolution of tumor in 60% of patients 16 weeks after treatment and partial resolution in 40%. All patients (100%) reported good aesthetic results and the most common adverse effects were fever (50%), arthralgia (40%), chills (35%), general malaise (35%), oedema (25%) and perilesional erythema (25%), all reversible after 12 hours of initial doses of treatment.
Conclusion: Combined interferon (HeberFERON) is a safe and effective option for treatment of basal cell carcinoma and provides a favourable clinical and aesthetic alternative when surgery is contraindicated.